Search Results - liver+cancer

5 Results Sort By:
A Viral Exposure Signature to Define and Detect Early Onset Hepatocellular Carcinoma
Abstract: Early detection of liver cancer, such as hepatocellular carcinoma (HCC), is key to improve cancer-related mortality. More than 800,000 people are diagnosed with this cancer each year throughout the world. Liver cancer is also a leading cause of cancer deaths worldwide, accounting for more than 700,000 deaths each year. Currently, millions...
Published: 4/8/2024   |   Inventor(s): Xin Wei Wang, Jinping Liu, Wei Tang
Keywords(s): Biomarker, HCC, hepatocellular carcinoma, Liver cancer, viral infection, Wang
Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Application > Diagnostics
Single-domain monoclonal antibodies for the treatment of hepatocellular carcinoma
Abstract: The National Cancer Institute seeks parties to license human monoclonal antibodies and immunoconjugates and co-develop, evaluate, and/or commercialize large-scale antibody production and hepatocellular carcinoma (HCC) xenograft mouse models. An advantage of these monoclonal antibodies as a potential therapeutic is their specificity, which...
Published: 5/21/2024   |   Inventor(s): Mitchell Ho, Mingqian Feng, Dimiter Dimitrov, Heungnam Kim, Wei Gao
Keywords(s): Antibody-drug Conjugate, chimeric antigen receptor, HCC, hepatocellular carcinoma, IMMUNOTOXINS, Liver cancer
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology
Development and Characterization of the SLC46A3 Knockout Mouse Line
Abstract: Nonalcoholic fatty liver disease is caused by several factors including 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), an environmental contaminant. TCDD causes lipid accumulation in humans by inducing the Solute Carrier Family 46 Member 3 (SLC46A3) gene expression. To effectively study TCDD-mediated lipid accumulation, research tools such as...
Published: 4/8/2024   |   Inventor(s): Frank Gonzalez, Sun Hee Yim, Jung-Hwan Kim
Keywords(s): 2, 3, 7, 8-tetracholodibenzo-p-dioxin, Gonzalez, hepatocellular carcinoma, Knockout Mouse, Liver cancer, Major Facilitator Superfamily, MFS, Nonalcoholic fatty liver disease, OBESITY, SLC46A3, Solute Carrier Family, TCDD
Category(s): TherapeuticArea > Oncology, Collaboration Sought > Licensing, Application > Research Materials, TherapeuticArea > Endocrinology
IgG4 Hinge Containing Nanobody-based CARs Targeting GPC3 for Treating Liver Cancer
Abstract: Hepatocellular carcinoma (HCC) is the most common type of liver cancer. Globally, HCC is the sixth most prevalent cancer and third leading cause of cancer-related morbidity. Standard treatment for HCC is not suitable for a large proportion of liver cancer patients. Part of this is because less than a quarter of HCC patients are surgical candidates...
Published: 5/21/2024   |   Inventor(s): Mitchell Ho, Aarti Kolluri, Nan Li
Keywords(s): ANTIBODY, cancer therapeutic, Chimeric antigen receptors (CARs), Glypican-3 (GPC3), Hepatocellular Carcinoma (HCC), HO, IgG4, Liver cancer, Macrophage, NANOBODY, Natural Killer (NK) Cell, T cell, therapeutic
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics
Bile Acids and Other Agents that Modulate the Gut Microbiome for the Treatment of Liver Cancer
Abstract: Primary liver tumors and secondary hepatic malignancies are among the leading causes of cancer-related deaths. Liver metastases account for 95% of all hepatic cancers, and the liver is the most common site for organ metastasis in the body. The gut microbiome serves an important role in antitumor immunity regulating the efficacy of chemo- and...
Published: 4/8/2024   |   Inventor(s): Tim Greten, Chi Ma
Keywords(s): Bile Acid, Greten, Liver cancer, Natural Killer T Cells, NKT cells
Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing
© 2024. All Rights Reserved. Powered by Inteum